Alvotech’s AVT05, a proposed biosimilar candidate to Simponi and Simponi Aria (golimumab), has entered its first pharmacokinetic study.
Alvotech’s Simponi Rival Begins Pharmacokinetic Study
The Icelandic Firm Is Also Expanding Its Marketing Partnership With Fuji Pharma
Alvotech’s Simponi rival enters Phase I trials after a dynamic year for the company’s development and commercialization program. Meanwhile, the biosimilars developer has also expanded its Japanese collaboration with Fuji Pharma.
